BACKGROUND AND PURPOSE: Treatment with selective oestrogen receptor modulators (SERMs) reduces low-density lipoprotein (LDL) cholesterol levels. We assessed the effect of tamoxifen, raloxifene and toremifene and their combinations with lovastatin on LDL receptor activity in lymphocytes from normolipidaemic and familial hypercholesterolaemic (FH) subjects, and human HepG2 hepatocytes and MOLT-4 lymphoblasts. EXPERIMENTAL APPROACH: Lymphocytes were isolated from peripheral blood, treated with different compounds, and 1,1'-dioctadecyl-3,3,3,3'-tetramethylindocarbocyanine perchlorate (DiI)-labelled LDL uptake was analysed by flow cytometry. KEY RESULTS: Tamoxifen, toremifene and raloxifene, in this order, stimulated DiI-LDL uptake by lymphocytes by inhibiting LDL-derived cholesterol trafficking and subsequent down-regulation of LDL receptor expression. Differently to what occurred in HepG2 and MOLT-4 cells, only tamoxifen consistently displayed a potentiating effect with lovastatin in primary lymphocytes. The SERM-mediated increase in LDL receptor activity was not altered by the anti-oestrogen ICI 182,780 nor was it reproduced by 17β-oestradiol. However, the tamoxifen-active metabolite endoxifen was equally effective as tamoxifen. The SERMs produced similar effects on LDL receptor activity in heterozygous FH lymphocytes as in normal lymphocytes, although none of them had a potentiating effect with lovastatin in heterozygous FH lymphocytes. The SERMs had no effect in homozygous FH lymphocytes. CONCLUSIONS AND IMPLICATIONS: Clinically used SERMs up-regulate LDL receptors in primary human lymphocytes. There is a mild enhancement between SERMs and lovastatin of lymphocyte LDLR activity, the potentiation being greater in HepG2 and MOLT-4 cells. The effect of SERMs is independent of oestrogen receptors but is preserved in the tamoxifen-active metabolite endoxifen. This mechanism may contribute to the cholesterol-lowering action of SERMs.
BACKGROUND AND PURPOSE: Treatment with selective oestrogen receptor modulators (SERMs) reduces low-density lipoprotein (LDL) cholesterol levels. We assessed the effect of tamoxifen, raloxifene and toremifene and their combinations with lovastatin on LDL receptor activity in lymphocytes from normolipidaemic and familial hypercholesterolaemic (FH) subjects, and human HepG2 hepatocytes and MOLT-4 lymphoblasts. EXPERIMENTAL APPROACH: Lymphocytes were isolated from peripheral blood, treated with different compounds, and 1,1'-dioctadecyl-3,3,3,3'-tetramethylindocarbocyanine perchlorate (DiI)-labelled LDL uptake was analysed by flow cytometry. KEY RESULTS:Tamoxifen, toremifene and raloxifene, in this order, stimulated DiI-LDL uptake by lymphocytes by inhibiting LDL-derived cholesterol trafficking and subsequent down-regulation of LDL receptor expression. Differently to what occurred in HepG2 and MOLT-4 cells, only tamoxifen consistently displayed a potentiating effect with lovastatin in primary lymphocytes. The SERM-mediated increase in LDL receptor activity was not altered by the anti-oestrogen ICI 182,780 nor was it reproduced by 17β-oestradiol. However, the tamoxifen-active metabolite endoxifen was equally effective as tamoxifen. The SERMs produced similar effects on LDL receptor activity in heterozygous FH lymphocytes as in normal lymphocytes, although none of them had a potentiating effect with lovastatin in heterozygous FH lymphocytes. The SERMs had no effect in homozygous FH lymphocytes. CONCLUSIONS AND IMPLICATIONS: Clinically used SERMs up-regulate LDL receptors in primary human lymphocytes. There is a mild enhancement between SERMs and lovastatin of lymphocyte LDLR activity, the potentiation being greater in HepG2 and MOLT-4 cells. The effect of SERMs is independent of oestrogen receptors but is preserved in the tamoxifen-active metabolite endoxifen. This mechanism may contribute to the cholesterol-lowering action of SERMs.
Authors: C Baigent; A Keech; P M Kearney; L Blackwell; G Buck; C Pollicino; A Kirby; T Sourjina; R Peto; R Collins; R Simes Journal: Lancet Date: 2005-09-27 Impact factor: 79.321
Authors: J Martínez-Botas; Y Suárez; A Reshef; P Carrero; H Ortega; D Gómez-Coronado; J L Teruel; E Leitersdorf; M A Lasunción Journal: Metabolism Date: 1999-07 Impact factor: 8.694
Authors: Thomas J Berrodin; Qi Shen; Elaine M Quinet; Matthew R Yudt; Leonard P Freedman; Sunil Nagpal Journal: Mol Pharmacol Date: 2010-09-13 Impact factor: 4.436
Authors: William Insull; Michael H Davidson; Pandurang M Kulkarni; Suresh Siddhanti; Angelina V Ciaccia; Cheryl A Keech Journal: Metabolism Date: 2005-07 Impact factor: 8.694
Authors: R P Naoumova; A D Marais; J Mountney; J C Firth; N B Rendell; G W Taylor; G R Thompson Journal: Atherosclerosis Date: 1996-01-26 Impact factor: 5.162
Authors: María E Fernández-Suárez; Joan C Escolà-Gil; Oscar Pastor; Alberto Dávalos; Francisco Blanco-Vaca; Miguel A Lasunción; Javier Martínez-Botas; Diego Gómez-Coronado Journal: Sci Rep Date: 2016-09-07 Impact factor: 4.379
Authors: Amirhossein Sahebkar; Maria-Corina Serban; Peter Penson; Camelia Gurban; Sorin Ursoniu; Peter P Toth; Steven R Jones; Giuseppe Lippi; Kazuhiko Kotani; Karam Kostner; Manfredi Rizzo; Jacek Rysz; Maciej Banach Journal: Drugs Date: 2017-07 Impact factor: 9.546
Authors: Ying Gong; Roel G J Klein Wolterink; Ian Janssen; Arjan J Groot; Gerard M J Bos; Wilfred T V Germeraad Journal: Mol Ther Methods Clin Dev Date: 2020-03-29 Impact factor: 6.698
Authors: Alberto Canfrán-Duque; Luis C Barrio; Milagros Lerma; Gema de la Peña; Jorge Serna; Oscar Pastor; Miguel A Lasunción; Rebeca Busto Journal: Int J Mol Sci Date: 2016-03-18 Impact factor: 5.923